INTERNATIONAL LIVER CANCER ASSOCIATION
ILCA 2025 Annual Conference19 - 21 November, 2025. Hong Kong
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P-01 | Molecular-based therapies for primary liver cancers: real-world data from 120 patients of the 2025 French Genomic Medicine Initiative | Claudia Campani |  Received |
 |
|||
| P-04 | Charting single-cell metabolism co-evolution during metastasis | Yingcheng Wu | Received |
|
|||
| P-08 | MEFV dysfunction Promotes Hepatocellular Carcinoma Progression via Inflammasome Activation | Hyunjae Shin | Received |
|
|||
| P-15 | Evolution of second-line practices in the era of immunotherapy: real-life data from the French prospective CHIEF cohort | Marie DECRAECKER | Received |
|
|||
| P-17 | Long - Chain Acyl - CoA Synthetase 4 (ACSL4): A Newly - Identified Driver at the Hepatocellular Carcinoma Invasive Front Governing Tumor Invasion, Metastasis and Patient Prognosis | Yusufukadier Maimaitinijiati | Received |
|
|||
| P-22 | Early Detection of Hepatocellular Carcinoma Using a Machine Learning-based Methylation Blood Test | Eun Ju Cho | Received |
|
|||
| P-23 | Kinase Suppressor of Ras 1 promotes carcinogenesis in liver via collaborating with c-Myc | Hyuk Moon | Received |
|
|||
| P-29 | Lipophilic Statin Increases Sensitivity for Anticancer Therapy by Suppressing YAP/TAZ in the Experimental Hepatocellular Carcinoma Models | Jun Yong Park | Received |
|
|||
| P-34 | Taurocholic acid-decreased Lactobacillus intestinalis inhibit hepatocellular carcinoma antitumor immunity via a 5-HT/RORA/STING Signaling | Jingyuan Wen | Received |
|
|||
| P-38 | Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors | Yingcheng Wu | Received |
|
|||
| P-43 | RNA binding protein TIA1 Protects Hepatic Lipid Homeostasis and Prevents NAFLD-HCC through stress granule assembly | Rong Liu | Received |
|
|||
| P-57 | Aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study and a genetic causality analysis | Moon Haeng Hur | Received |
|
|||
| P-60 | Treatment outcomes of systemic therapies: infiltrative vs. multinodular hepatocellular carcinoma | Yu-Yun Shao | Received |
|
|||
| P-63 | Enhanced prediction of HBV-Related HCC using aMAP and liver stiffness assessed by Vibration-Controlled Transient Elastography | Hye Yeon Chon | Received |
|
|||
| P-64 | Detection and monitoring of HBV-related hepatocellular carcinoma from plasma cfDNA fragmentation profiles | Pin Cui | Received |
|
|||
| P-72 | Noncontrast Abbreviated MRI for Surveillance of Recurrent Hepatocellular Carcinoma After Tansarterial Chemoembolization | Sun Kyung Jeon | Received |
|
|||
| P-84 | Adverse Event Monitoring with Imaging: Prognostic Significance in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma | Jeayeon Park | Received |
|
|||
| P-95 | Development and Validation of a Risk Prediction Model for Patients with Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab | Heechul Nam | Received |
|
|||
| P-106 | A Study of the Efficacy and Safety of Hepatocellular Carcinoma Treatment by Radiofrequency Ablation with D-Sorbitol | RYOSUKE IMADO | Received |
|
|||
| P-107 | Combination of Hepatic Arterial Infusion Chemotherapy with Tyrosine Kinase Inhibitor Provides Better Survival in Advanced Hepatocellular Carcinoma Patients | Po Ting Lin | Received |
|
|||
| P-108 | Comparison of Treatment Efficacy and Safety Profile of Atezolizumab Plus Bevacizumab in BCLC B and C Patients with Hepatocellular Carcinoma | Jae Hyun Yoon | Received |
|
|||
| P-124 | Comparison of three methods for mapping organs at risk (OARs) in patients with liver cancer | Pei-Jin Tsai | Received |
|
|||
| P-127 | The impacts of human albumin on postoperative clinical outcomes in Chinese HCC patients treated with surgical operation: the REAL study | Tian He | Received |
|
|||
ILCA 2025 Annual Conference
19 - 21 November, 2025. Hong Kong
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 19/11/2025 TO 19/11/2026
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 12/11/2025
|
|
